Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IMO ! Any SELL decisions made at the current levels are premature ..
After January 24th BICX is in complete different phase as a promising company that owns a potentially FDA approved product
(BICX102)..
Before Jan 24th we were waiting for BIOCORRX to meet with the FDA .. well !! it happened and now waiting for updates which will come and the company will continue its exciting journey towards FDA approval ...
That is why I think that the price drop scenarios WILL NOT happen again like before Jan 24th ...
All my opinion ... GO BICX
IMO !! Selling at these levels is nonsense ... upward potential is very high and as soon as the FDA updates hits the market , the PPS will rise again !!
Biocorrx Inc. (OTCMKTS:BICX)’s Shares Drawing Attention From Keen Investors
?January 26, 2018 ?Nelson Research Staff
Shares of Biocorrx Inc. (OTCMKTS:BICX) have been in the headlines as its price reached $0.235 at the conclusion of the most trading day. The stock is traded on OTC in the Medical sector and Medical Services industry.
The mathematical calculation that represents the degree of change over time is known as “percentage change”. In finance, it serves many purposes, and is often used to represent the price change of a commodity.
Biocorrx Inc. (OTCMKTS:BICX)’s Price Change % over the last week is 9.3%. It’s % Price Change over the previous month is 113.64% and previous three months is [% Price Change (12 weeks)]. Finally, looking back over the past year-to-date, Biocorrx Inc. (OTCMKTS:BICX)’s Price Change % is 41.65%.
Percentage change can be applied to any quantity that is measured over time any given time period. Say you are tracking the price of a stock. If the price increased, the formula [(New Price – Old Price)/Old Price] is applied and then take that number and multiply it by 100. If the price of a stock decreased, the formula [(Old Price – New Price)/Old Price] is applied then multiplied by 100. The formula can be used to track the prices of both individual commodities and large market listings, and also used to compare the values of different currencies. Balance sheets with comparative financial statements often will include prices of specific stocks at different time periods alongside the percentage change over the same periods of time.
Average Volume is the amount of securities traded in a day on average over a specific time period. Trading activity relates to the liquidity of a security. When average volume is high, the stock has high liquidity and can be therefore easily traded, while conversely, when the trading volume is low, the commodity will be less expensive as traders are not as willing to purchase it. Average volume has an effect on the price of the security. Biocorrx Inc. (OTCMKTS:BICX) has seen 1234588.5 shares trade hands on average.
Biocorrx Inc. (OTCMKTS:BICX)’s 52-Week High-Low Range Price % is 81.3. Countless factors affect a security’s price and, therefore, its range.
1.6 million of the 1.85 million shares traded today so far are ALL BUYS .. tells you one thing about today's trading ... up we gooooo
Another/ Different BICX link
http://www.addiction-tx.com/page/biocorrx
Today's news is SOLID news .
Just a little break then off to another race . Healthy trading ..IMO !
The FDA potential approval is a big thing guys .. all the stocks that have FDA approved products are trading in the Dollar ranges ... go BICX
PARKER ...... Wwwwwwhere arrrrre youuuuuuu lol ... I see dead people hahaha !!!
Kizer ... I am staying quiet :) hard to do but will keep my promise lol
2nd PR OUT !!!
The Biotechnology Market is Projected to Grow
9:00 AM ET 1/26/18 | PR Newswire
BICX
0.24 0.00%
CRIS
0.70 0.00%
EGLT
0.93 0.00%
PLX
0.69 0.00%
PTN
0.94 0.00%
Quotes delayed at least 15 minutes
FinancialBuzz.com News Commentary
NEW YORK, January 26, 2018 /PRNewswire/ --
According to a report from Global Market Insights, the biotechnology market size was valued at over USD 330.3 billion in 2015 and is expected to exceed 775.2 billion by 2024, at a compound annual growth rate of 9.9 percent during the forecast year. Increasing demand of new technologies for chronic diseases continues to drive the biotechnology industry size. The industry is segmented into biopharmacy, bioagriculture, bioservices and bioindustrial based on application. Biopharmcy held the largest market share in 2015, with a revenue of over USD 199 billion. Based on region, North America holds the dominant position in term of revenue due to increasing R&D spending, in part due to growing papulation and increasing demands for a more effeicent healthcare industry. BioCorRx Inc. (OTC: BICX), Curis, Inc. (NASDAQ: CRIS), Egalet Corporation (NASDAQ: EGLT), Palatin Technologies, Inc. (NYSE: PTN), Protalix BioTherapeutics, Inc. (NYSE: PLX)
A major segment of the healthcare industry is substance abuse treatment. According to another report from Transparency Market Research, U.S. substance abuse treatment market was value at US$4.42 billion in 2015, and is expected to research US$12.43 Billion by 2024, at an impressive compound annual growth rate of 12.4 percent. Substance addiction includes alcohol dependence, tobacco/nicotine addiction, and opioid addiction. Rising number of people addicted to alcohol, nicotine/tobacco, and opioids boosted the demand for substance abuse treatment in the U.S. The report indicated that the demand of outpatient treatment centers is expected to grow rapidly in the coming year due to increasing Popularity of Outpatient Rehab
BioCorRx Inc. (OTCQB: BICX) earlier in the week company announced breaking news that, "a pilot for the BioCorRx(R) Recovery Program in collaboration with the One Day at a Time Program (ODAAT), a program funded by the city of Philadelphia and state of Pennsylvania. This will be a paid demonstration pilot in which the BioCorRx Recovery Program will be used to treat several individuals suffering from opioid and alcohol use disorders. The ODAAT program assists over 56,000 residents of Philadelphia.
ODAAT is dedicated to serving low-income and homeless men and women and their families in the Philadelphia area who are afflicted by addiction and HIV/AIDS. ODAAT is also building stronger communities through their anti-violence and recovery initiatives. ODAAT's focus is on providing peer support and promoting healthy, positive lifestyles. ODAAT accomplishes its mission through a holistic array of services, including addiction recovery counseling, linkage to health and social services, transitional housing, and community outreach. The BioCorRx(R) Recovery Program includes the use of a naltrexone implant produced per patient prescription, combined with the Company's proprietary cognitive behavioral therapy (CBT) program and overlapping 12 months of peer support. These specifically formulated, biodegradable pellets are typically inserted beneath the skin in the lower abdominal area. Naltrexone is a non-addictive opioid antagonist used for the treatment of alcohol and opioid use disorders. It can reduce or eliminate cravings for alcohol and opioids, as well as block the dangerous effects of opioid use such as overdose, as commonly seen with heroin. The implant provides a window of opportunity for one to get through the behavioral therapy component and well established into the peer support portion of the program.
Mel Wells, President of One Day at a Time Program, commented: "As recovery providers, we cannot continue to sit by and watch our loved ones and family members die. Thanks to BioCorRx's support and expertise, together we will be able to make a resounding impact in saving lives against addiction."
Pennsylvania State Senator Sharif Street, stated, "Given the tremendous challenges placed on the community by the opioid epidemic, I am excited that One Day at A Time continues to be a leader and innovator in the recovery space. One Day at a Time has a track record of helping people overcome addiction and I am hopeful that they are equally successful in the implementation of this new, innovative and potentially lifesaving process for addressing opioid addiction and recovery."
Brady Granier, President, CEO and Director of BioCorRx, stated: "We are pleased to have such great support for our recovery program in Pennsylvania. The BioCorRx(R) Recovery Program continues to gain momentum as independent treatment providers across the country report successful results using our program to treat their patients."
Tom Welch, VP Operations of BioCorRx commented: "We are thrilled to be working with Mel, ODAAT and the great people of Pennsylvania. We look forward to making a significant and positive impact in this insidious epidemic."
Curis, Inc. (NASDAQ: CRIS) is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Recently, the company announced initiation of patient dosing in a Phase 1 trial of CA-4948, an orally available small molecule inhibitor of the IRAK4 kinase, for treatment of patients with lymphoma. CA-4948 was discovered at Aurigene and is the second licensed program from the Curis-Aurigene collaboration to enter the clinic. The Phase 1 study is designed to evaluate the safety, tolerability, and pharmacokinetic profile of CA-4948; identify any dose-limiting toxicities; and establish the recommended Phase 2 dose for the treatment of patients with lymphomas. The dose escalation stage of the trial will enroll patients with relapsed/refractory non-Hodgkin's lymphoma, and the expansion stage will focus on specific populations of patients with lymphomas harboring alterations in the MYD88 gene or Toll-like receptor (TLR) signaling pathway.
Egalet Corporation (NASDAQ: EGLT), a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Recently, the company announced that its partner OraPharma, a division of Valeant Pharmaceuticals International, Inc., has begun promoting SPRIX(R) (ketorolac tromethamine) Nasal Spray to more than 9,000 dentists and oral surgeons across the United States. Under the agreement announced earlier this month, the OraPharma sales team will promote SPRIX Nasal Spray along with their own portfolio of products to their target dentists and oral surgeons. SPRIX Nasal Spray is a nonsteroidal anti-inflammatory drug (NSAID) indicated in adults for short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level.
Palatin Technologies, Inc. (NYSE: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. On January 3, 2018, the company announced that the U.S. Food and Drug Administration (FDA) has notified Palatin that it may proceed with its clinical investigation of subcutaneous injection PL-8177 as a potential treatment for patients with ulcerative colitis. The notice to proceed was received following Palatin's submission of an investigational new drug (IND) application for this program. Palatin expects to commence a Phase 1 single and multiple ascending dose study in the current quarter. PL-8177, a selective melanocortin receptor 1 (MC1r) agonist peptide, is Palatin's lead clinical development candidate for ulcerative colitis and other inflammatory bowel diseases. Agents that modulate the MC1r system may have therapeutic potential in a variety of inflammatory disease indications.
Protalix BioTherapeutics, Inc. (NYSE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). On January, 02, 2018, the company announced interim data from the first 14 patients that completed, to date, the Company's phase II clinical trial of OPRX-106 (oral anti-TNF) in patients with ulcerative colitis. The phase II clinical trial is a randomized, open label, 2-arm study of OPRX-106 in patients with active mild to moderate ulcerative colitis. A total of 24 patients were enrolled and randomized to receive 2 mg or 8 mg of OPRX-106, administered orally, once daily, for 8 weeks. The first 14 patients have completed the study, and four patients are currently in treatment and follow-up. The trial evaluated key efficacy endpoints including clinical response and remission utilizing the Mayo score, as well as safety and pharmacokinetics.
Subscribe Now! Watch us report from LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
(MORE TO FOLLOW) Dow Jones Newswires
January 26, 2018 09:00 ET (14:00 GMT)
The Biotechnology Market is Projected to Grow -2-
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. FinancialBuzz.com has not been compensated by any companies mentioned. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news dissemination and PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com .
For further information:
Media Contact: info@financialbuzz.com , +1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com
> Dow Jones Newswires
January 26, 2018 09:00 ET (14:00 GMT)
IMO ! Current PPS will be history in no time specially with the updates flow coming soon from the FDA meeting minutes ... feeling Very good and positive ... GO BICX !!!
ALL POSITIVE !!! Meeting took place on time , FDA gave the green light for BICX102 , more updates coming soon from the meeting minutes , NOTHING NEGATIVE AT ALL !!! Love it :)
Hey "Kizer" ... I am staying quiet today !!! no PPS predictions :) may be will work
what's so special about the 0.24s lol
Some of the latest PRs hit between 11 & 1 pm ... fingers crossed
loving the recent action on the PPS .. IMO best time to jump back in before it hits several pennies ...
its going to be a challenging trading day .. if you are an investor that wants to get in today before the " potentially " good news expected any minute but didn't then you would lose a Huge profit making opportunity ..
It comes down to how much you believe in BICX ... good luck ALL ...
You know me very well "Kizer" . I keep checking all my resources every 30 minutes or so ...LOL
and I won't predict the PPS today so it won't drop :) HAHAHAHA
Nice close :)
Haha !!! Love it :)
Random Question :
Does anyone happen to know what time during the day the FDA meeting should take place ?
BioCorRx Announces Collaboration with the One Day at a Time Program in Philadelphia
January 24, 2018 07:30 ET | Source: BioCorRx Inc
ANAHEIM, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced a pilot for the BioCorRx® Recovery Program in collaboration with the One Day at a Time Program (ODAAT), a program funded by the city of Philadelphia and state of Pennsylvania. This will be a paid demonstration pilot in which the BioCorRx Recovery Program will be used to treat several individuals suffering from opioid and alcohol use disorders. The ODAAT program assists over 56,000 residents of Philadelphia.
ODAAT is dedicated to serving low-income and homeless men and women and their families in the Philadelphia area who are afflicted by addiction and HIV/AIDS. ODAAT is also building stronger communities through their anti-violence and recovery initiatives. ODAAT’s focus is on providing peer support and promoting healthy, positive lifestyles. ODAAT accomplishes its mission through a holistic array of services, including addiction recovery counseling, linkage to health and social services, transitional housing, and community outreach.
The BioCorRx® Recovery Program includes the use of a naltrexone implant produced per patient prescription, combined with the Company’s proprietary cognitive behavioral therapy (CBT) program and overlapping 12 months of peer support. These specifically formulated, biodegradable pellets are typically inserted beneath the skin in the lower abdominal area. Naltrexone is a non-addictive opioid antagonist used for the treatment of alcohol and opioid use disorders. It can reduce or eliminate cravings for alcohol and opioids, as well as block the dangerous effects of opioid use such as overdose, as commonly seen with heroin. The implant provides a window of opportunity for one to get through the behavioral therapy component and well established into the peer support portion of the program.
Mel Wells, President of One Day at a Time Program, commented, “As recovery providers, we cannot continue to sit by and watch our loved ones and family members die. Thanks to BioCorRx's support and expertise, together we will be able to make a resounding impact in saving lives against addiction.”
Pennsylvania State Senator Sharif Street, stated, “Given the tremendous challenges placed on the community by the opioid epidemic, I am excited that One Day at A Time continues to be a leader and innovator in the recovery space. One Day at a Time has a track record of helping people overcome addiction and I am hopeful that they are equally successful in the implementation of this new, innovative and potentially lifesaving process for addressing opioid addiction and recovery.”
Brady Granier, President, CEO and Director of BioCorRx, stated, “We are pleased to have such great support for our recovery program in Pennsylvania. The BioCorRx® Recovery Program continues to gain momentum as independent treatment providers across the country report successful results using our program to treat their patients.”
Tom Welch, VP Operations of BioCorRx commented, “We are thrilled to be working with Mel, ODAAT and the great people of Pennsylvania. We look forward to making a significant and positive impact in this insidious epidemic.”
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
Related Articles
More articles issued by BioCorRx Inc
what's so special about the 0.24s lol
Freeeeeeeeeeeeeeeeeze !!!
Hahaha ... trust me . Will work one time ...
Will see you guys @ 0.30 + here very soon .... Go BICX
Gearing for a bull run? Xli Technologies Inc (XLIT) Moves 38.30% For Week
?January 22, 2018 ?Elena Sutton
Xli Technologies Inc (XLIT) shares are showing positive signals short-term as the stock has finished higher by 38.30% for the week. In taking a look at recent performance, we can see that shares have moved -22.62% over the past 4-weeks, -69.05% over the past half year and -30.85% over the past full year.
Investors often have to figure out how aggressive they want to be when getting into the stock market. There are individuals who may have had some initial success based on random luck, but diving without preparation can leave investors on the short end of the stick in the long run. Investors may be tempted by the next hot stock that is being talked about around the water cooler. Investors might not realize how risky a certain stock may be, and they may find out that the over performer has already made the run. Doing all the homework may involve tracking technicals, fundamentals, current economic data, and earnings releases. Putting in the time to do the proper research may help the investor see profits down the road.
Currently, Xli Technologies Inc (XLIT) has a 14-day Commodity Channel Index (CCI) of 107.04. The CCI technical indicator can be employed to help figure out if a stock is overbought or oversold. CCI may also be used to aid in the discovery of divergences that could possibly signal reversal moves. A CCI closer to +100 may provide an overbought signal, and a CCI near -100 may offer an oversold signal.
Tracking other technical indicators, the 14-day RSI is presently standing at 51.10, the 7-day sits at 65.09, and the 3-day is resting at 88.28 for Xli Technologies Inc (XLIT). The Relative Strength Index (RSI) is a highly popular technical indicator. The RSI is computed base on the speed and direction of a stock’s price movement. The RSI is considered to be an internal strength indicator, not to be confused with relative strength which is compared to other stocks and indices. The RSI value will always move between 0 and 100. One of the most popular time frames using RSI is the 14-day.
Perfect time to average down and buy more ... upward trend started .. :)
100 % Something BIG is up .....
BID RISING SLOWLY ........
BICX STOCK LIVE ANALYSIS 1-22-18 !! VERY INTERESTING ....NEXT WALL 0.26-0.28 ....... VERY SOON GUYS :)
Some positive action happening lately !!! 100K buy this morning
Won't be surprised if the PPS started trading between 0.30 & 0.40 soon ....
.30
People been dying to get in cheaper ... too late loooooool